Search
Fenoterol
go.drugbank.com/drugs/DB01288ApprovedWithdrawnFenoterol is an adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
Synonyms: 1-(p-hydroxyphenyl)-2-((β-hydroxy-β-(3',5'-dihydroxyphenyl))ethyl)aminopropane, 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diolInternational brands: Berotec NPitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigationalIn a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. … Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. … Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].
Categories: CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesAminophenazone
go.drugbank.com/drugs/DB01424ApprovedWithdrawnThe FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942] … In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests.
Categories: Non COX-2 selective NSAIDS, Cytochrome P-450 SubstratesSynonyms: 4-Dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one, 1-Phenyl-2,3-dimethyl-4-(dimethylamino)-5-pyrazoloneBuserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalBuserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). … It is used in prostate cancer treatment.
Products: Suprefact Depot 2 Months, SUPREFACT INJECTABLE 1 mg/mlOveporexton
go.drugbank.com/drugs/DB21680ApprovedOveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1). … [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDiiodohydroxyquinoline
go.drugbank.com/drugs/DB09115ApprovedDiiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. … Iodoquinol is not currently available in any FDA-approved products.
Mixtures: GYNECON - T, Iodoquinol 1% - Hydrocortisone Acetate 2% - Aloe Polysaccharides 1%Categories: Heterocyclic Compounds, 2-RingDengue virus serotype 4
go.drugbank.com/drugs/DB22667ApprovedDengue virus serotype 4 is a serotype of _Orthoflavivirus denguei_ known to cause dengue fever. … [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Synonyms: Dengue virus type 4, Dengue virus serotype 4Vinorelbine
go.drugbank.com/drugs/DB00361ApprovedInvestigationalIt was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid. … Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998].
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 5'-NoranhydrovinblastineAbemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VERZENIO® 100 MG, VERZENIO® 150 MG